Is testosterone treatment dangerous for the cardiovascular system in older hypogonadal men?

IJC Metabolic and Endocrine

Volumn 4, Issue , 2014, Pages 1-3

  Aversa, Antonio ^a   Francomano, Davide ^a   Lenzi, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Aging; Diabetes; Frailty; Male hypogonadism; Metabolic syndrome; Obesity

Indexed keywords

AGED; CANCER STAGING; CASE REPORT; CHEMOTHERAPY; COLON FISTULA; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DECOMPRESSION; DIGESTIVE STENT; EDITORIAL; HUMAN; ILEOSTOMY; INTESTINE RESECTION; LAPAROSCOPY; LOSS OF APPETITE; MALE; PALLIATIVE THERAPY; POSITRON EMISSION TOMOGRAPHY; RECTAL STENT; RECTOSCOPY; SIGMOID CARCINOMA; WEIGHT REDUCTION;

EID: 84908030284     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2014.08.001     Document Type: Editorial

References (12)

1. Wu F.C.W., Tajar A., Beynon J.M., Pye S.R., Silman A.J., Finn J.D., et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010, 363:123-135.
2. Lunenfeld B., Mskhalaya G., Kalinchenko S., Tishova Y. Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men - a suggested update. Aging Male 2013, 16:143-150.
3. Corona G., Rastrelli G., Monami M., Guay A., Buvat J., Sforza A., et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011, 165:687-701.
4. Basaria S., Coviello A., Travison T., Storer T.W., Farwell W.R., Jette A.M., et al. Adverse events associated with testosterone administration. N Engl J Med 2010, 363:109-122.
5. Vigen R., O'Donnell C.I., Barón A.E., Grunwald G.K., Maddox T.M., Bradley S.M., et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. J Am Med Assoc 2013, 310:1829-1836.
6. Bhasin S., Cunningham G.R., Hayes F.J., Matsumoto A.M., Snyder P.J., Swerdloff R.S., et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010, 95:2536-2559.
7. Traish A.M., Guay A.T., Morgentaler A., Androgen Study Group, et al. Death by testosterone? We think not!. J Sex Med 2014, 11:624-629.
8. Xu L., Freeman G., Cowling B., Schooling C.M. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled trials. BMC Med Apr 18 2013, 11:108. 10.1186/1741-7015-11-108.
9. Finkle W.D., Greenland S., Ridgeway G.K., Adams J.L., Frasco M.A., Cook M.B., et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014, 9:e85805. [eCollection]. 10.1371/journal.pone.0085805.
10. Aversa A., Bruzziches R., Francomano D., Rosano G., Isidori A.M., Lenzi A., et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010, 7:3495-3503.
11. Malkin C.J., Pugh P.J., Morris P.D., Kerry K.E., Jones R.D., Jones T.H., et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 2004, 90:871-876.
12. Toma M., McAlister F.A., Coglianese E.E., Vidi V., Vasaiwala S., Bakal J.A., et al. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 2012, 5:315-321.